European Study Commences for Ancora Heart's AccuCinch Ventricular Repair System for Heart Failure Treatment

 

August 12, 2019—Ancora Heart, Inc. announced the first patient was enrolled in the CorCinch EU study. The study is a European multicenter clinical evaluation of the company's AccuCinch ventricular repair system as a treatment for patients with reduced ejection fraction systolic heart failure (HFrEF). The study will enroll up to 132 patients from heart centers across Europe.

The first patient was enrolled at Homolka Hospital in Prague, Czech Republic by Professor Petr Neužil, MD, Head of the Department of Cardiology at Homolka Hospital and Principal Investigator of the study. The AccuCinch procedure was completed by coinvestigator Vivek Reddy, MD, along with Prof. Neužil. Dr. Reddy is Director of Cardiac Arrhythmia Services at The Mount Sinai Hospital in New York, New York.

In the company's announcement, Prof. Neužil commented, "The transcatheter AccuCinch therapy is unique in its ventricular approach, which is intended to improve heart function by repairing the left ventricle for patients with systolic heart failure regardless of its origin. We are pleased to participate in this study because the AccuCinch has the potential to address the shortcomings of current medical, surgical, and transcatheter treatments and restore quality of life and longevity for this large patient population.”

According to Ancora Heart, this is the company's second recently initiated study evaluating the AccuCinch system focused specifically on heart failure and the enlarged left ventricle. Earlier this year, the company announced that the first patient was enrolled in a United States early feasibility study evaluating the AccuCinch system as a treatment for patients with HFrEF.

The transcatheter AccuCinch therapy is designed to complement and enhance the existing care to further manage symptoms and slow, or stop, the progression of heart failure. For some patients, AccuCinch may have the potential to reverse the enlargement of the left ventricle. For patients where heart failure has progressed beyond the ability for medications and pacemakers to manage symptoms, nonsurgical percutaneous device therapy with AccuCinch may provide an effective treatment option. The AccuCinch system is designed to directly repair the left ventricle of the heart, thereby addressing the fundamental issue in the progression of systolic heart failure, state Ancora Heart.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.